Anlotinib Dihydrochloride |
AL-3818 |
Approved |
Chiatai Tianqing (CTTQ), Advenchen Laboratories |
Anlotinib Hydrochloride Capsules |
cfda |
Non small cell lung cancer (NSCLC), Soft tissue sarcoma, Small cell lung cancer (SCLC) |
|
2018-05-08 |
Small cell lung cancer (SCLC), Non small cell lung cancer (NSCLC), Soft tissue sarcoma |
Details
|
Ancestim |
AMJ-9302 |
Approved |
Amgen, SOBI |
|
|
|
|
|
Stem cell mobilization |
Details
|
Imatinib mesylate |
STI-571; CGP-57148B; CGP-57148; CTI-571; QTI-571,CGP57148B,STI 571,STI571,CGP 57148B |
Approved |
Novartis |
GLEEVEC |
fda |
Gastrointestinal stromal tumors (GISTs), Chronic myeloid leukemia (CML ) |
NOVARTIS |
2001-05-10 |
Myelodysplastic syndrome (MDS), Myeloproliferative Disorders (MPD), Gastrointestinal stromal tumors (GISTs), Aggressive systemic mastocytosis (ASM), Hypereosinophilic syndrome (HES), Dermatofibrosarcoma protuberans (DFSP), Chronic eosinophilic leukemia (CEL), Acute lymphoblastic leukaemia (ALL), Chronic myeloid leukemia (CML ) |
Details
|
Sorafenib Tosylate |
BAY-54-9085; BAY-43-9006; BAY-43-0006; NSC-724772,BAY 43-9006,BAY54-9085,BAY43-9006,BAY 54-9085 |
Approved |
Onyx Pharmaceutical, Bayer |
NEXAVAR |
fda |
Differentiated thyroid cancer, Advanced renal cell carcinoma (RCC), Unresectable hepatocellular carcinoma |
BAYER HLTHCARE |
2005-12-01 |
Differentiated thyroid cancer, Renal cell carcinoma, Advanced renal cell carcinoma (RCC), Unresectable hepatocellular carcinoma, Hepatocellular carcinoma (HCC) |
Details
|
Regorafenib Monohydrate |
BAY-73-4506; DAST,BAY73-4506,BAY 73-4506,BAY-734506 |
Approved |
Bayer, Onyx Pharmaceutical |
STIVARGA |
fda |
Gastrointestinal stromal tumors (GISTs), Metastatic colorectal cancer (CRC) |
BAYER HLTHCARE |
2012-09-27 |
Gastrointestinal stromal tumors (GISTs), Liver cancer, Metastatic colorectal cancer (CRC), Hepatocellular carcinoma (HCC) |
Details
|
Pexidartinib |
PLX-3397 |
Approved |
Daiichi Sankyo |
TURALIO |
fda |
Tenosynovial giant cell tumor (TGCT) |
DAIICHI SANKYO INC |
2019-08-02 |
Tenosynovial giant cell tumor (TGCT) |
Details
|
Lenvatinib Mesylate |
E-7080; ER-203492-00,E7080 |
Approved |
Eisai |
LENVIMA |
fda |
Thyroid cancer |
EISAI INC |
2015-02-13 |
Differentiated thyroid cancer, Renal cell carcinoma, Advanced renal cell carcinoma (RCC), Thyroid cancer, Unresectable hepatocellular carcinoma, Hepatocellular carcinoma (HCC) |
Details
|
Sunitinib Malate |
PNU-290940; SU-11248; SU-010398; SU-011248-L-malate salt; PHA-290940; PHA-290940AD; PNU-290940AD; GB-102,SU11248,PNU 290940,PNU290940,SU 11248 |
Approved |
Pfizer |
SUTENT |
fda |
Renal cell carcinoma, Gastrointestinal stromal tumors (GISTs), Advanced renal cell carcinoma (RCC), Pancreatic neuroendocrine tumors (pNET) |
CPPI CV |
2006-01-26 |
Renal cell carcinoma, Gastrointestinal stromal tumors (GISTs), Advanced renal cell carcinoma (RCC), Pancreatic neuroendocrine tumors (pNET), Renal carcinoma |
Details
|
Ponatinib Hydrochloride |
AP-24534; AP24534 HCl; AP24534 hydrochloride; AP24534-HCL; INCB-84344,AP 24534,AP24534 |
Approved |
Ariad |
ICLUSIG |
fda |
Acute lymphoblastic leukaemia (ALL), Chronic myeloid leukemia (CML ) |
ARIAD |
2012-12-14 |
Acute lymphoblastic leukaemia (ALL), Chronic myeloid leukemia (CML ) |
Details
|
Avapritinib |
BLU-285,BLU-285; CS-3007 |
Approved |
Blueprint Medicines, CStone Pharmaceuticals |
AYVAKIT |
fda |
|
BLUEPRINT MEDICINES |
2020-01-09 |
Gastrointestinal stromal tumors (GISTs) |
Details
|
Cabozantinib S-malate |
XL-184; BMS-907351,BMS907351,XL184,XL 184,BMS 907351 |
Approved |
Exelixis, Ipsen, Takeda |
COMETRIQ |
fda |
Medullary thyroid cancer (MTC) |
EXELIXIS |
2012-11-29 |
Renal cell carcinoma, Advanced renal cell carcinoma (RCC), Medullary thyroid cancer (MTC), Hepatocellular carcinoma (HCC) |
Details
|
Pazopanib Hydrochloride |
GW-786034; GSK-786034; GW-786034B ; SB-786034,GW786034,GW 786034 |
Approved |
GlaxoSmithKline, Novartis |
VOTRIENT |
fda |
Renal cell carcinoma, Soft tissue sarcoma |
NOVARTIS |
2009-10-19 |
Renal cell carcinoma, Soft tissue sarcoma, Soft tissue infections, Renal carcinoma |
Details
|
Midostaurin |
PKC-412; CGP-41231; CGP-41251; PKC-412A |
Approved |
Novartis |
RYDAPT |
fda |
Systemic mastocytosis with associated hematological neoplasm, Aggressive systemic mastocytosis (ASM), Acute myeloid Leukemia (AML), Mast cell leukemia |
NOVARTIS |
2017-04-28 |
Systemic mastocytosis with associated hematological neoplasm, Aggressive systemic mastocytosis (ASM), Acute myeloid Leukemia (AML), Mast cell leukemia |
Details
|
Ripretinib |
DCC-2618 |
Approved |
Deciphera, Zai Lab |
QINLOCK |
fda |
|
DECIPHERA PHARMS |
2020-05-15 |
Gastrointestinal stromal tumors (GISTs), Aggressive systemic mastocytosis (ASM), Malignancies |
Details
|
Dasatinib Hydrate |
BMS-354825; NSC-732517 ,BMS354825,BMS 354825 |
Approved |
Bristol-Myers Squibb |
SPRYCEL |
fda |
Acute lymphoblastic leukaemia (ALL), Chronic myeloid leukemia (CML ) |
BRISTOL MYERS SQUIBB |
2006-06-28 |
Acute lymphoblastic leukaemia (ALL), Chronic myeloid leukemia (CML ) |
Details
|